Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BT-20 | TNBC | Basal A | Trastuzumab | HER2 | ErbB | 0.0115 | uM | 5903.102 | 0.9945 | 0.9912 | 1.2557 | |
| BT-20 | TNBC | Basal A | Trastuzumab | HER2 | ErbB | 0.0576 | uM | 5903.102 | 1.0224 | 1.0356 | 1.2557 | |
| BT-20 | TNBC | Basal A | Trastuzumab | HER2 | ErbB | 0.288 | uM | 5903.102 | 0.9567 | 0.9307 | 1.2557 | |
| BT-20 | TNBC | Basal A | Trastuzumab | HER2 | ErbB | 1.44 | uM | 5903.102 | 1.0751 | 1.1186 | 1.2557 | |
| BT-20 | TNBC | Basal A | Trastuzumab | HER2 | ErbB | 7.2 | uM | 5903.102 | 1.0492 | 1.0780 | 1.2557 | |
| BT-474 | HER2amp | Luminal | Trastuzumab | HER2 | ErbB | 0.0000184 | uM | 9158.123 | 0.9400 | 0.8638 | 0.8769 | |
| BT-474 | HER2amp | Luminal | Trastuzumab | HER2 | ErbB | 0.0000922 | uM | 9158.123 | 0.9863 | 0.9687 | 0.8769 | |
| BT-474 | HER2amp | Luminal | Trastuzumab | HER2 | ErbB | 0.000461 | uM | 9158.123 | 1.0159 | 1.0362 | 0.8769 | |
| BT-474 | HER2amp | Luminal | Trastuzumab | HER2 | ErbB | 0.0023 | uM | 9158.123 | 0.8740 | 0.7152 | 0.8769 | |
| BT-474 | HER2amp | Luminal | Trastuzumab | HER2 | ErbB | 0.0115 | uM | 9158.123 | 0.7040 | 0.3404 | 0.8769 | |
| BT-474 | HER2amp | Luminal | Trastuzumab | HER2 | ErbB | 0.0576 | uM | 9158.123 | 0.7380 | 0.4144 | 0.8769 | |
| BT-474 | HER2amp | Luminal | Trastuzumab | HER2 | ErbB | 0.288 | uM | 9158.123 | 0.6783 | 0.2846 | 0.8769 | |
| BT-474 | HER2amp | Luminal | Trastuzumab | HER2 | ErbB | 1.44 | uM | 9158.123 | 0.6332 | 0.1876 | 0.8769 | |
| BT-474 | HER2amp | Luminal | Trastuzumab | HER2 | ErbB | 7.2 | uM | 9158.123 | 0.5398 | -0.0100 | 0.8769 | |
| BT-474 | HER2amp | Luminal | Trastuzumab | HER2 | ErbB | 0.0000184 | uM | 9163.026 | 0.9666 | 0.8262 | 0.3738 | |
| BT-474 | HER2amp | Luminal | Trastuzumab | HER2 | ErbB | 0.0000922 | uM | 9163.026 | 0.9979 | 0.9887 | 0.3738 | |
| BT-474 | HER2amp | Luminal | Trastuzumab | HER2 | ErbB | 0.000461 | uM | 9163.026 | 0.9786 | 0.8874 | 0.3738 | |
| BT-474 | HER2amp | Luminal | Trastuzumab | HER2 | ErbB | 0.0023 | uM | 9163.026 | 0.8267 | 0.2022 | 0.3738 | |
| BT-474 | HER2amp | Luminal | Trastuzumab | HER2 | ErbB | 0.0115 | uM | 9163.026 | 0.6608 | -0.3398 | 0.3738 | |
| BT-474 | HER2amp | Luminal | Trastuzumab | HER2 | ErbB | 0.0576 | uM | 9163.026 | 0.6797 | -0.2881 | 0.3738 | |
| BT-474 | HER2amp | Luminal | Trastuzumab | HER2 | ErbB | 0.288 | uM | 9163.026 | 0.6649 | -0.3288 | 0.3738 | |
| BT-474 | HER2amp | Luminal | Trastuzumab | HER2 | ErbB | 1.44 | uM | 9163.026 | 0.6395 | -0.3950 | 0.3738 | |
| BT-474 | HER2amp | Luminal | Trastuzumab | HER2 | ErbB | 7.2 | uM | 9163.026 | 0.5106 | -0.6688 | 0.3738 | |
| BT-483 | HR+ | Luminal | Trastuzumab | HER2 | ErbB | 0.0000184 | uM | 9186.026 | 1.0355 | 1.1412 | 0.5108 | |
| BT-483 | HR+ | Luminal | Trastuzumab | HER2 | ErbB | 0.0000922 | uM | 9186.026 | 1.0300 | 1.1192 | 0.5108 |